Tom 20, Nr 4 (2024)
Opis przypadku
Opublikowany online: 2025-02-12
Wyświetlenia strony
328
Wyświetlenia/pobrania artykułu
123
Wtrętowe zapalenie mięśni – opis przypadku z odniesieniem do kryteriów diagnostycznych z 2024 roku
1, 1
, 1, 2, 2, 2, 1
, 1, 2, 2, 2, 1
DOI: 10.5603/ppn.103648
Pol. Przegl. Neurol 2024;20(4):216-225.
Streszczenie
W pracy opisano przypadek 82-letniej kobiety z zaburzeniami chodu, osłabieniem kończyn dolnych oraz z dysfagią, u której na podstawie badań neurofizjologicznych, biopsji mięśnia i wyników laboratoryjnych rozpoznano wtrętowe zapalenie mięśni (IBM, inclusion body myositis). W artykule omówiono najnowsze koncepcje IBM jako choroby autoimmunologicznej ale także zwyrodnieniowej. Wtrętowe zapalenie mięśni cechuje się stopniowym osłabieniem mięśni, często asymetrycznym, z zajęciem głębokich zginaczy palców, prostowników kolan. Choć spotykane są i inne, mniej typowe wzorce zajęcia mięśni. Zagadnienie badań pomocniczych niezbędnych do przeprowadzenia diagnostyki różnicowej zostało omówione na podstawie najnowszych kryteriów diagnostycznych wtrętowego zapalenia mięśni z 2024 roku.
Słowa kluczowe: wtrętowe zapalenie mięśnikryteria diagnostyczne
Referencje
- Phillips B, Zilko P, Mastaglia F. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle & Nerve. 2000; 23(6): 970–972, doi: 10.1002/(sici)1097-4598(200006)23:6<970::aid-mus20>3.0.co;2-i.
- Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology. 2000; 55(9): 1385–1387.
- Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci. 2008; 15(12): 1350–1353.
- Callan A, Capkun G, Vasanthaprasad V, et al. A systematic review and meta-analysis of Prevalence studies of sporadic inclusion body myositis. J Neuromuscul Dis. 2017; 4(2): 127–137.
- Shelly S, Mielke MM, Mandrekar J, et al. Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology. 2021; 96(21): e2653–e2661.
- Lejuste F, Thomas L, Picard G, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016; 3(5): e280.
- Li Ke, Pu C, Huang X, et al. Clinicopathologic features of sporadic inclusion body myositis in China. Neurol Neurochir Pol. 2015; 49(4): 245–250.
- Dimachkie MM, Barohn RJ. Inclusion body myositis. Semin Neurol. 2012; 32(3): 237–245.
- Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991; 325(21): 1487–1498.
- Camargo L, Carvalho M, Shinjo S, et al. Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis. BioMed Research International. 2018; 2018: 1–15.
- Mastaglia FL. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. Acta Myol. 2009; 28(2): 66–71.
- Hossain MdM, Wilkerson J, McGrath JA, et al. The geospatial distribution of myositis and its phenotypes in the United States and associations with roadways: findings from a national myositis patient registry. Front Med (Lausanne). 2022; 9: 842586.
- Uruha A, Noguchi S, Hayashi YK, et al. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology. 2016; 86(3): 211–217.
- Nelke C, Kleefeld F, Preusse C, et al. Inclusion body myositis and associated diseases: an argument for shared immune pathologies. Acta Neuropathol Commun. 2022; 10(1): 84.
- Văcăraş V, Vulturar R, Chiş A, et al. Inclusion body myositis, viral infections, and TDP-43: a narrative review. Clin Exp Med. 2024; 24(1): 91.
- Matsuura E, Umehara F, Nose H, et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol. 2008; 67(1): 41–49.
- Misterska-Skóra M, Sebastian A, Dzięgiel P, et al. Inclusion body myositis associated with Sjögren's syndrome. Rheumatol Int. 2013; 33(12): 3083–3086.
- Rojana-udomsart A, James I, Castley A, et al. High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes. J Neuroimmunol. 2012; 250(1-2): 77–82.
- Naddaf E. Inclusion body myositis: update on the diagnostic and therapeutic landscape. Front Neurol. 2022; 13.
- Weihl CC, Dalal S, Pestronk A, et al. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum Mol Genet. 2006; 15(2): 189–199.
- Dalakas MC. Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006; 2(8): 437–447.
- Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One. 2011; 6(5): e20266.
- Salam S, Dimachkie MM, Hanna MG, et al. Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis. Clin Exp Rheumatol. 2022; 40(2): 384–393.
- Tawara N, Yamashita S, Zhang X, et al. Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. Ann Neurol. 2017; 81(4): 512–525.
- Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013; 73(3): 408–418.
- Mendell JR, Sahenk Z, Gales T, et al. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol. 1991; 48(12): 1229–1234.
- Haczkiewicz K, Sebastian A, Piotrowska A, et al. Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series. Rheumatol Int. 2019; 39(7): 1291–1301.
- Askanas V, Engel WK, Bilak M, et al. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol. 1994; 144(1): 177–187.
- Chen X, Miller NM, Afghah Z, et al. Development of AD-Like Pathology in Skeletal Muscle. J Parkinsons Dis Alzheimers Dis. 2019; 6(1).
- Broccolini A, Gidaro T, Morosetti R, et al. Hereditary inclusion-body myopathy: clues on pathogenesis and possible therapy. Muscle Nerve. 2009; 40(3): 340–349.
- Meyer H, Weihl CC. The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. J Cell Sci. 2014; 127(Pt 18): 3877–3883.
- Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014; 83(5): 426–433.
- Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996; 40(4): 581–586.
- Lilleker JB, Naddaf E, Saris CGJ, et al. 272nd ENMC workshop participants. 272nd ENMC international workshop: 10 Years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands. Neuromuscul Disord. 2024; 37: 36–51.
- Rose MR. ENMC IBM Working Group. 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013; 23(12): 1044–1055.
- Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine (Baltimore). 2001; 80(5): 320–327.
- Namsrai T, Parkinson A, Chalmers A, et al. Diagnostic delay of myositis: an integrated systematic review. Orphanet J Rare Dis. 2022; 17(1): 420.
- Michelle EH, Pinal-Fernandez I, Casal-Dominguez M, et al. Clinical subgroups and factors associated with progression in patients with inclusion body myositis. Neurology. 2023; 100(13): e1406–e1417.
- Abdelnaby R, Mohamed KA, Elgenidy A, et al. Muscle sonography in inclusion body myositis: a systematic review and meta-analysis of 944 measurements. Cells. 2022; 11(4).
- Zubair AS, Salam S, Dimachkie MM, et al. Imaging biomarkers in the idiopathic inflammatory myopathies. Front Neurol. 2023; 14.
- Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997; 48(3): 712–716.
- Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000; 247(1): 22–28.
- Hanna MG, Badrising UA, Benveniste O, et al. RESILIENT Study Group. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019; 18(9): 834–844.
- Machado PM, McDermott MP, Blaettler T, et al. Arimoclomol in IBM Investigator Team of the Neuromuscular Study Group. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023; 22(10): 900–911.
